15 Useful Amazon Products Worth Ordering This Month
The Shopping Trends team is independent of the journalists at CTV News. We may earn a commission when you use our links to shop. Read about us.
Amazon Canada is a treasure trove of useful products. But with so many options, it can be difficult to determine what's actually worth the spend. To help you out, we've done the digging, scrolling through the site and digging deep into the reviews to find items that'll make your life a little easier. Here are a few useful Amazon products you'll want to add to your cart this month:
Sign up for an Amazon Prime account if Amazon Canada is your go-to site for shopping. It costs $99 a year (plus tax), but students can get it for only $49 (plus tax). If you've never tried it out, you can sign up for a 30-day trial period.
Disclaimer: The prices displayed are accurate at the time of publication. We'll do our best to keep them as up-to-date as possible, but you may see slight changes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Unifor says former Canadian Auto Workers president Buzz Hargrove has died
Outgoing CAW NAtional President Buzz Hargrove Hargrove receives applause during his speech at the CAW Special Convention in Toronto, Saturday, Sept. 6, 2008. THE CANADIAN PRESS/Chris Young Canada's largest private-sector union says former Canadian Auto Workers president Buzz Hargrove has died. In a statement Sunday, Unifor says Basil 'Buzz' Hargrove was 'a beloved and iconic figure in Canada's labour movement' who 'was a tireless advocate for working people and a deeply respected leader.' Hargrove was national president of the CAW from 1992 until his retirement in 2008, shortly before he reached the union's mandatory retirement age of 65. The CAW merged with the Communications, Energy and Paperworkers Union in 2013 to become Unifor. Born in Bath, N.B., in 1944, Unifor says Hargrove grew up in a family of 10 children and began his working life on the shop floor of Chrysler's Windsor, Ont., assembly plant. As CAW president, Unifor says he led negotiations with major employers including General Motors, Ford, Chrysler, Air Canada and CN Rail, securing gains that elevated standards across sectors. 'He never forgot where he came from — and he carried that working-class spirit with him into every boardroom, bargaining session and public forum," said Unifor National President Lana Payne in the union's statement. 'His passion, his intellect, and his uncompromising belief in justice for working people shaped the labour movement we know today.' Hargrove took over leadership of the CAW from Bob White, who led the union as it split from the U.S.-based United Auto Workers in 1985. The Canadian union, which disagreed with the UAW's bargaining direction, negotiated some of the richest contracts for workers in Canada, and under Hargrove's leadership it expanded beyond the auto industry into other sectors, including the airlines, mines and fisheries. Unifor said that Hargrove was 'a committed social unionist,' and pushed the CAW to fight for broader social justice issues including public health care, retirement security, equity, and fair trade. 'We owe him a debt of gratitude for everything he did to build a fairer Canada,' Payne added. Hargrove told reporters upon his retirement that he wasn't planning on taking it easy. 'I'm not going to sit in a rocking chair and I'm not going to play golf, that's not my style,' Hargrove said at a news conference in Toronto in 2008. His later activities included over a year with the NHL Players' Association, working first on the union's advisory board and then as interim ombudsman. He also served as director of the Centre for Labour Management Relations at the Ted Rogers School of Management at Toronto Metropolitan University. Hargrove was named an Officer of the Order of Canada in 2008. Unifor said details on a celebration of his life and legacy will be shared in the coming days.
National Post
an hour ago
- National Post
Satellos Bioscience to Participate in PPMD's Annual Conference in Las Vegas
Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada. Article content The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to improving outcomes for people living with Duchenne. Satellos will be onsite to engage with the Duchenne community, listen to families' experiences, and share updates on its science and mission to regenerate muscle from within. Article content Article content 'We're looking forward to connecting in person with families and advocates who are at the heart of this work,' said Frank Gleeson, Co-founder and CEO of Satellos. 'This conference is a powerful reminder of why we're focused on developing a new approach to treat Duchenne — one that aims to restore the body's ability to repair muscle.' Article content Attendees can meet members of the Satellos team throughout the event and learn more by visiting the company's booth in the exhibition hall. Article content About Satellos Bioscience Inc. Article content Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Article content This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. Article content Article content Article content Article content Article content Contacts Article content Investors: Article content Liz Williams, CFO, Article content ir@ Article content Article content Media: Article content Emily Williams, Senior Director, Communications, Article content Article content Article content
CTV News
an hour ago
- CTV News
STM maintenance workers resume strike for two more days
A special constable from the Société de transport de Montréal (STM) locks the doors to the metro station due to the strike from STM maintenance workers in Montreal on Monday, June 9, 2025. (THE CANADIAN PRESS/Christinne Muschi) After a pause for the Formula 1 Grand Prix weekend, maintenance workers at the Société de transport de Montréal (STM) are resuming their strike for two more days. On Monday and Tuesday, bus and Metro services will run during the morning and afternoon rush hours, as well as late in the evening. Outside these times, service will be reduced to 50 per cent. The strike by the 2,400 STM maintenance workers began last Monday. During the first phase of the strike, there was no service outside of essential hours, causing headaches for public transport users. The strike was suspended for the Grand Prix weekend, with safety concerns cited as the reason for the pause due to the large number of people expected to travel to Île Notre-Dame for the event. The nine-day strike by the Fédération des employé(e)s des services publics union, affiliated with the Confédération des syndicats nationaux (CSN), is scheduled to end on Tuesday at 10 p.m. The first mediation meeting between STM management and the maintenance workers' union is scheduled to take place on Monday. Last Friday, the mediator appointed by Quebec met separately with STM management and the union to familiarize himself with the case and each party's position. Outsourcing is currently one of the main points of contention. Stuck with a tight budget, the STM says it needs flexibility. Meanwhile, the union argues it is fighting against the privatization of certain services and for the preservation of public service jobs. – This report by The Canadian Press was first published in French on June 16, 2024.
